IP Group H1 NAV Rises to 113.9p as Pfizer Obesity Asset Surges

IP Group reported a 3.2% increase in net asset value per share to 113.9 pence for the first half of 2026, driven by a valuation surge in its Pfizer obesity royalty asset and sharply higher cash realizations. Total NAV reached £1 billion, reflecting stronger portfolio performance compared to the prior period.

"Our priority is execution and converting that opportunity into outcomes that shareholders can see and measure," said Greg Smith, Chief Executive, IP Group, in a statement regarding the results.

Portfolio Valuations and Cash Realizations

The financial gains were led by the performance of the IP Group portfolio, specifically the company's royalty asset tied to Pfizer obesity treatments. That asset was valued at £152 million following clinical developments, including the progression of a berobenatide and amylin combination into Phase 2b development.

Cash realizations reached £68.7 million in the first half of 2026, surpassing the total amount realized during the whole of 2025. Following the close of the reporting period, IP Group noted that net asset value per share climbed further to approximately 117 pence, while year-to-date cash proceeds expanded to £85.8 million.

What Is Driving Biotech Royalty Valuations?

Royalty assets represent a contractual right to a percentage of future product revenues or milestone payments, removing the direct operational costs of drug manufacturing and commercialization from the holder's balance sheet. For venture investors like IP Group, clinical milestones, such as entering Phase 2b trials, trigger upward valuation adjustments under accounting standards as the probability of regulatory approval increases.

Market Position and Capital Allocation

The capital inflows from cash realizations provide IP Group with additional liquidity to support its early-stage science and technology portfolio. As the firm navigates public market conditions, the accelerated pace of asset monetizations addresses historical investor scrutiny regarding the realization timeline of university spin-out portfolios.